Objective: To report a patient with chronic blepharospasm possibly induced by the calcium-channel blocker cinnarizine.
Case report: A 53-year-old woman developed chronic blepharospasm during a prolonged therapy with calcium-channel blocker cinnarizine for the treatment of vertigo.
Conclusions: "Tardive blepharospasm" should be considered as a possible adverse effect of cinnarizine.